SCHEMBL719683

SCHEMBL719683

COc1cccc(-n2cc(C)c(C(O)C3CCCCC3)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.42
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TP53 P04637 1/20 0.39
CCR1 P32246 1/20 0.38
NOTUM Q6P988 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CTSS P25774 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717195 0.87 IDO1 (0.42) SMN1; SMN2ALDH1A1MEN1KMT2ATP53
SCHEMBL718338 0.84 BCHE (0.41) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL717877 0.84 BCHE (0.42) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL719184 0.79 PDE4A (0.43) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL719334 0.79 BCHE (0.40) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL717720 0.78 HPGD (0.39) SMN1; SMN2ALDH1A1LMNAL3MBTL1ADORA2A
SCHEMBL717876 0.73 IDO1 (0.38) CYP1A2CYP3A4CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL3398378 0.72 BCHE (0.39) BCHEMAPK1MEN1KMT2ANOTUM
SCHEMBL718340 0.71 IDO1 (0.41) SMN1; SMN2ALDH1A1MEN1KMT2ATP53
SCHEMBL720040 0.71 NOTUM (0.46) BCHESMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP BCHE 1649/4885CYP1A2 774/4885CYP3A4 834/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP BCHE 1649/4885CYP1A2 774/4885CYP3A4 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.